Royalties. In consideration of Mosaic’s contributions to the Research and the licenses granted to Catalyst hereunder, beginning with the first commercial sale of Products in a country of the Territory by Catalyst, its Affiliates or Sublicensees, Catalyst shall pay Mosaic a running royalty of: ​.

Royalties. In consideration for the license granted to [[AntriaBio:Organization]] herein, during the Licensed Product Royalty Term, [[AntriaBio:Organization]] shall pay royalties to XOMA on Net Sales of Products by [[AntriaBio:Organization]], its Affiliates and (sub)licensees in the Territory as follows:

Royalties. In further consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall pay to Licensor a royalty of ​ on Net Sales of Licensed Products, subject to the reductions in royalty rates set forth in [Section 3.4.1].

Royalties. SAVARA shall pay GEMA royalties in accordance with [Exhibit 6.3].

Royalties. In further consideration of the licenses and other rights granted to Coya, subject to Section 5.5 (Royalty Adjustments) and [Section 5.6] (Sublicensing Income), on a country-by-country basis, Coya shall pay to ARScience Bio royalties in the amount of the marginal royalty rates set forth in the table below (“Royalty Rates”) based on the aggregate Net Sales resulting from the sale of all Products in the Territory during each Calendar Year of the applicable Royalty Term for each Product in each country (the “Annual Net Sales,” and such payments, “Royalties”).

Royalties. With respect to each Allogene Licensed Product and subject to the provisions of Section 5.2.2, Allogene will pay [[Cellectis:Organization]] royalties in the amount of the applicable rates (“Marginal Royalty Rates”) set forth below of Annual Net Sales of any Allogene Licensed Product Targeting such Allogene Target during the Royalty Term:

Royalties. Beginning on the First Commercial Sale of any [[Organization A:Organization]] Licensed Product in a country, and ending upon expiration or termination of the Term, [[Organization A:Organization]] will pay [[Agenus:Organization]] a royalty on Net Sales of the Licensed Product by [[Organization A:Organization]] and its Affiliates in such country, calculated by multiplying the applicable royalty rate by the aggregate amount of Annual Net Sales of such Licensed Product in the Territory during the applicable calendar year (the “Royalty”):

Royalties. Subject to Section 4.4, Earned Royalties will accrue on a Licensed Product-by-Licensed Product basis and country-by-country basis, for the duration of the Royalty Term and will be payable to Institute when Licensed Products are invoiced, or if not invoiced, when delivered or otherwise exploited by the Licensee, its Affiliate or Sublicensee in a manner constituting a Sale.

Royalties. For any Quarter in which Net Sales Per Unit of Customer Product (other than Customer Product sold under any COVAX Supply Agreement or GAVI Customer AP Agreement) exceed the Unit Threshold Price, Customer shall pay to Dynavax a royalty equal to ​ of the amount determined by multiplying # Adjusted Net Sales Per Unit in such Quarter, by # Units Sold in such Quarter. For clarity, no royalties shall be payable under this [Section 6.4] # for any portion of Net Sales Per Unit of Customer Product that does not exceed the Unit Threshold Price or # on any sales of Customer Product under any COVAX Supply Agreement or GAVI Customer AP Agreement.

Royalties. During the applicable Royalty Term and subject to Section 8.5, Kyorin will make non-refundable, non-creditable royalty payments to aTyr, on a Licensed Product-by-Licensed Product basis, based on aggregate Annual Net Sales of such Licensed Product in the Kyorin Territory by Kyorin and its Related Parties at the royalty rates set forth below: